Ligand Acquires XOMA Royalty for $739 Million, Bolstering Royalty Portfolio
Event summary
- Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for $39.00 per share, totaling approximately $739 million in equity value.
- The acquisition will expand Ligand’s royalty portfolio to over 200 assets and add seven commercial products.
- Ligand expects the transaction to be immediately accretive to adjusted EPS, increasing 2026 guidance to $8.50-$9.50 and adding $1.50 per share in 2027.
- XOMA Royalty stockholders will receive a Contingent Value Right (CVR) tied to potential proceeds from ongoing litigation with Janssen Biotech.
The big picture
Ligand’s acquisition of XOMA Royalty underscores the growing trend of royalty aggregation within the biopharmaceutical sector, as companies seek to diversify revenue streams and reduce reliance on individual drug approvals. This $739 million deal positions Ligand as a leading player in this space, competing with other aggregators to secure attractive royalty assets. The deal also highlights the increasing importance of litigation outcomes in the valuation of biopharma assets, as evidenced by the CVR structure.
What we're watching
- Litigation Risk
- The value of the CVRs represents a potential upside but also introduces uncertainty, as the outcome of the litigation with Janssen Biotech remains unresolved and could impact the overall return on investment.
- Integration Execution
- Ligand’s ability to successfully integrate XOMA Royalty’s portfolio and teams will be crucial to realizing the anticipated synergies and avoiding operational disruptions.
- Portfolio Diversification
- How Ligand manages the expanded portfolio of over 200 assets, balancing growth opportunities with potential risks, will determine the long-term success of the acquisition.
Related topics